Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating activities:
Net loss	$ (3,154,181)	$ (15,465,912)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	39,767	19,520
Loss on sale or disposal of assets		6,761
Stock-based compensation expense	973,950	1,121,990
Common stock issued for advisory services	50,000	1,409,363
Warrant related expense, change in fair value, and other financing expenses	(5,813,720)
Abandonment of in-process research and development intangible asset		951,000
Change in deferred income taxes		(364,796)
Settlement of litigation matter		2,500,000
Non-cash interest expense, net	11,967	7,067
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	(661,675)	50,918
Accounts payable, accrued expenses and other liabilities	(1,496,150)	410,014
Net cash used in operating activities	(10,050,042)	(9,354,075)
Cash flows (used in) provided by investing activities:
Purchases of property and equipment	(438,604)	(2,331)
Purchase of certificate of deposit	(10,000,000)
Cash received in reverse merger transaction		8,500,602
Net cash (used in) provided by investing activities	(10,438,604)	8,498,271
Cash flows provided by financing activities:
Proceeds from the sale of Series A convertible preferred stock and warrants, net	22,129,774
Payment of offering costs for Series B	(97,980)
Repayment of convertible debt	(1,880,000)
Proceeds from the issuance of convertible debt		1,880,000
Net cash provided by financing activities	20,151,794	1,880,000
Net (decrease) increase in cash and cash equivalents	(336,852)	1,024,196
Cash and cash equivalents at beginning of period	1,552,852	1,997,192
Cash and cash equivalents at end of period	1,216,000	3,021,388
Supplemental disclosure of cash flow information:
Cash paid for interest	112,800
Supplemental disclosure of non-cash investing and financing activities:
Series A cumulative preferred dividends	(912,946)
Conversion of accrued dividends related to convertible preferred stock	187,172
Conversion of convertible notes and related accrued interest into common stock		711,495
Consideration in connection with RestorGenex Corporation merger transaction		21,261,000
Series A Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Series A cumulative preferred dividends	(912,946)
Conversion of accrued dividends related to convertible preferred stock	200,000
Convertible Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activities:
Conversion of accrued dividends related to convertible preferred stock	$ 187,172